Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabhalta
Pharma
Second Novartis drug in IgAN troika crosses FDA finish line
The FDA's approval for Novartis' atrasentan in the kidney disease IgAN means Chinook Therapeutics investors will see a $160 million payday.
Angus Liu
Apr 3, 2025 10:56am
Novartis' Fabhalta nod in C3G leaves room for rival Apellis
Mar 21, 2025 10:37am
CHMP again backs Leqembi amid flurry of approval recommendations
Feb 28, 2025 10:30am
Novartis, Apellis roll out rival datasets in rare kidney disease
Oct 28, 2024 10:03am
Novartis’ Fabhalta wins expanded FDA nod in IgAN
Aug 8, 2024 3:18am
Novartis rides IgAN trioka to trial wins in rare kidney diseases
May 28, 2024 11:20am
